4D Molecular Therapeutics (FDMT) Receivables (2019 - 2022)
4D Molecular Therapeutics (FDMT) posted quarterly Receivables of $700000.0 for Q4 2022, down 6.29% year-over-year from $747000.0 in Q4 2021, and down 6.29% quarter-over-quarter from $747000.0 in Q4 2021.
4D Molecular Therapeutics (FDMT) Receivables (2019 - 2022) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Receivables for 4 consecutive years, with $700000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Receivables fell 6.29% year-over-year to $700000.0; the TTM figure through Dec 2022 stood at $700000.0 (down 6.29% YoY), while the FY2022 annual figure was $700000.0, down 6.29% from the prior year.
- Receivables retreated to $700000.0 in Q4 2022 per FDMT's latest filing, from $747000.0 in the prior quarter.
- Across five years, Receivables topped out at $1.2 million in Q2 2021 and bottomed at $561000.0 in Q1 2021.
- Historically, Receivables has averaged $836714.3 across 4 years, with a median of $749000.0 in 2019.
- Annual changes were most pronounced in 2020 — Receivables jumped 46.86% — and 2021, when it slumped 32.09%.
- 4D Molecular Therapeutics' Receivables stood at $749000.0 in 2019, then jumped by 46.86% to $1.1 million in 2020, then plunged by 32.09% to $747000.0 in 2021, then decreased by 6.29% to $700000.0 in 2022.
- Business Quant data shows FDMT's Receivables at $700000.0 in Q4 2022, $747000.0 in Q4 2021, and $800000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 700,000.00 |
| Dec 31, 2021 | 747,000.00 |
| Sep 30, 2021 | 800,000.00 |
| Jun 30, 2021 | 1.20 Mn |
| Mar 31, 2021 | 561,000.00 |
| Dec 31, 2020 | 1.10 Mn |
| Dec 31, 2019 | 749,000.00 |